Press releases

July 19, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more
July 17, 2024

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program

Read more
June 20, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more
June 13, 2024

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Read more
June 12, 2024

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Read more
June 12, 2024

Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

Read more
June 11, 2024

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

Read more
June 04, 2024

Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference

Read more
May 30, 2024

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Read more
May 17, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more